Polymer particles
Biodegradable, cross-linked polymer particle embolics and methods of making the same are described. The particle embolics can be used as embolization agents.
1. An embolic composition including:
polymer particles comprising at least one monomer including at least one functional group, at least one crosslinker having a structure
at least one pharmaceutical agent.
2. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is a positively charged pharmaceutical agent.
3. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is a negatively charged pharmaceutical agent.
4. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is irinotecan, doxorubicin, epirubicin, idarubicin, or a combination thereof.
5. The embolic composition of claim 1 , wherein the polymer particles have a diameter between about 40 μm and about 1,200 μm.
6. The embolic composition of claim 1 , wherein the polymer particles have a diameter between about 75 μm and about 1,200 μm.
7. The embolic composition of claim 1 , wherein the at least one functional group is acrylate, acrylamide, methacrylate, or methacrylamide.
8. The embolic composition of claim 1 , wherein the at least one monomer includes an ionizable functional group.
9. The embolic composition of claim 8 , wherein the ionizable functional group is basic.
10. The embolic composition of claim 8 , wherein the ionizable functional group is acidic.
11. The embolic composition of claim 1 , wherein the polymer particles include a second crosslinker including a second linkage selected from an ester, a thioester, a carbonate, a peptide cleavable by matrix metalloproteinases, a peptide cleavable by matrix collagenases, a peptide cleavable by matrix elastases, and a peptide cleavable by matrix cathepsins.
12. The embolic composition of claim 1 , wherein the polymer particles are biodegradable.
13. The embolic composition of claim 1 , wherein the polymer particles are substantially degraded within about 1 months of implantation.
14. The embolic composition of claim 1 , wherein the at least one monomer is dimethylacrylamide.
15. The embolic composition of claim 1 , wherein the at least one monomer is acrylamide.
16. The embolic composition of claim 1 , wherein the at least one pharmaceutical agents is at least 90% eluted over the first day of implantation.
17. The embolic composition of claim 1 , wherein the at least one pharmaceutical agents is at least 60% eluted over the first day of implantation.
18. The embolic composition of claim 1 , wherein the at least one pharmaceutical agent is at a highest concentration in situ less than about 1 hour after implantation.
19. A method of treatment, the method comprising:
delivering the embolic solution of claim 1 through a delivery device to a treatment site.
20. The method of claim 19 , wherein the delivering is through a catheter, a microcatheter, or a needle.